Table 3.
Pre- and post-treatment clinical characteristics of T2DM patients treated with sitagliptin
| Group | Changes after sitagliptin | P value | ||
|---|---|---|---|---|
| Pre-treatment (n = 32) | Post-treatment (n = 32) | |||
| BMI, kg/m2 | 26.16 ± 3.44 | 25.69 ± 3.58 | − 0.47 (− 0.79, − 0.16) | 0.005* |
| TC, mmol/l | 4.79 ± 0.91 | 4.73 ± 0.83 | − 0.06 (− 0.26, 0.15) | 0.572 |
| LDL-C, mmol/l | 3.07 ± 0.92 | 3.04 ± 0.93 | − 0.03 (− 0.27, 0.21) | 0.813 |
| HDL-C, mmol/l | 1.14 ± 0.26 | 1.19 ± 0.33 | 0.05 (− 0.01, 0.11) | 0.075 |
| TG, mmol/l | 1.72 (1.20, 2.25) | 1.37 (0.98, 2.33) | − 0.09 (− 0.46, 0.28) | 0.114 |
| FBG, mmol/l | 8.51 ± 1.71 | 6.66 ± 1.17 | − 1.85 (− 2.38, − 1.31) | < 0.001* |
| FINS, μIU/ml | 9.65 (6.15, 14.85) | 9.65 (5.63, 12.85) | − 0.17 (− 1.75, 1.40) | 0.888 |
| HbA1c, % | 8.05 ± 0.81 | 6.61 ± 0.62 | − 1.44 (− 1.75, − 1.13) | < 0.001* |
| HOMA-IR | 3.51 (2.03, 5.62) | 2.70 (1.67, 3.99) | − 0.87 (− 1.43, − 0.31) | 0.006* |
| HOMA-β | 40.83 (23.06, 58.33) | 66.92 (35.57, 87.86) | 24.30 (13.47, 35.14) | < 0.001* |
| Irisin, ng/ml | 10.03 ± 2.06 | 11.18 ± 1.91 | 1.15 (0.70, 1.60) | < 0.001* |
Data shown as mean ± standard deviation were compared between pre- and post-treatment using paired Student’s t-test
Data shown as median (interquartile range) were compared between pre- and post-treatment using paired Wilcoxon test
BMI body mass index, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglyceride, FBG fasting blood glucose, FINS fasting insulin, HbA1c glycosylated hemoglobin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-β homeostasis model assessment of β-cell function
*P < 0.05